Speaker | Stefan Ledinger, MA BSc
Affiliation | biocrates life sciences, Innsbruck, Austria
Metabolomics as a tool to stratify patients and guide therapeutic decisions
In spite of major advances in the treatment of numerous diseases, non-response and loss of response to therapy is still an important topic. In addition, actionable biomarkers are largely missing for indications beyond oncology, as well as for the choice of supportive therapy. Here, metabolomics can be used to develop tools to help guide therapy decisions in multiple ways, e.g. predict whether a drug will be effective, choose the best course of therapy, or monitor therapies along the patient journey.
Related videos
Host-microbial interactions as pathophysiological nexus in inflammatory bowel disease
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Related articles
- Precision medicine – Transform medicine with metabolomics – part 3 of 5
- Propionic acid – A short-chain fatty acid with big impact
- Predictive medicine – Transform medicine with metabolomics – part 2 of 5
- N-acetyl-aspartic acid (NAA) – Significant metabolite for brain function, metabolism, and disease
- Preventive medicine – Transform medicine with metabolomics – part 1 of 5